1. Home
  2. FTK vs ABUS Comparison

FTK vs ABUS Comparison

Compare FTK & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flotek Industries Inc.

FTK

Flotek Industries Inc.

N/A

Current Price

$24.04

Market Cap

924.7M

Sector

Industrials

ML Signal

N/A

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

N/A

Current Price

$5.11

Market Cap

1.0B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FTK
ABUS
Founded
1985
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
924.7M
1.0B
IPO Year
1997
2008

Fundamental Metrics

Financial Performance
Metric
FTK
ABUS
Price
$24.04
$5.11
Analyst Decision
Buy
Strong Buy
Analyst Count
1
1
Target Price
$20.00
$5.00
AVG Volume (30 Days)
670.7K
4.2M
Earning Date
05-05-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
147.06
55.26
EPS
0.38
0.84
Revenue
$136,092,000.00
$14,083,000.00
Revenue This Year
$13.33
N/A
Revenue Next Year
$16.38
$239.71
P/E Ratio
$61.95
$6.14
Revenue Growth
214.53
128.21
52 Week Low
$11.43
$3.50
52 Week High
$39.67
$5.45

Technical Indicators

Market Signals
Indicator
FTK
ABUS
Relative Strength Index (RSI) 39.73 61.60
Support Level $15.27 $4.99
Resistance Level $25.39 $5.42
Average True Range (ATR) 1.32 0.14
MACD -0.41 -0.00
Stochastic Oscillator 19.61 54.23

Price Performance

Historical Comparison
FTK
ABUS

About FTK Flotek Industries Inc.

Flotek Industries Inc is a technology-driven specialty chemistry and data company. It has two reportable segments: Its Chemistry Technologies segment includes specialty chemistries, logistics and technology services. It also include integrated oil and gas companies, oilfield services companies, independent oil and gas companies, national and state-owned oil companies, and international supply chain management companies. The Data Analytics segment provides analytical measurement solutions and deliver real-time information and insights to customers to enable optimization of operations and reduction of emissions and their carbon intensity. Key revenue comes from its Chemistry Technologies segment.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: